Summary:
In 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes, semaglutide 2.4 mg subcutaneous weekly for 52 weeks significantly improved KCCQ-CSS (+13.7 vs +6.4 points, difference 7.3, P<0.001), weight (-9.8% vs -3.4%), 6MWD, and CRP levels compared to matching placebo, with fewer serious adverse events (17.7% vs 28.8%).
| PICO | Description |
|---|---|
| Population | 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes. |
| Intervention | Semaglutide 2.4 mg subcutaneous weekly for 52 weeks. |
| Comparison | Matching placebo weekly for 52 weeks. |
| Outcome | KCCQ +7.3 difference. Weight -9.8% vs -3.4%. Serious AEs 17.7% vs 28.8%. |
STEP-HFpEF DM: Semaglutide in HFpEF
RCT · obesity HFpEF + T2D · 52 wk
Semaglutide improved heart-failure symptoms and physical limitations and produced greater weight loss than placebo at 1 year, with fewer serious adverse events.
Clinical Context
HFpEF + diabetes + obesity creates compounded metabolic and hemodynamic derangements that traditional HF therapies inadequately address.
Clinical Pearls
1. Diabetes Presence Doesn’t Attenuate Benefits: KCCQ improvement comparable to non-diabetic STEP-HFpEF trial.
2. KCCQ Improvement Is Clinically Meaningful: 7.3 points exceeds 5-point threshold.
3. Inflammation Reduction: CRP reduction suggests anti-inflammatory effects.
4. Safety Advantage: Fewer serious AEs with semaglutide (17.7% vs 28.8%).
Practical Application
Prioritize semaglutide for HFpEF + obesity + T2D triad. Reassess diuretics as weight loss accumulates.
Study Limitations
52-week duration. Hard endpoints not powered. Highly selected population.
Bottom Line
Semaglutide produces clinically meaningful benefits in HFpEF + obesity + T2D with fewer serious AEs.
Source: Kosiborod MN, et al. “Semaglutide in Obesity-Related Heart Failure and Type 2 Diabetes.” NEJM, 2024. Read article